Skip to main content
Clinical Trials/CTRI/2019/02/017609
CTRI/2019/02/017609
Completed
Phase 2

Randomized Controlled Clinical study on the efficacy of Vidangadi Lauha on Sthula Madhumeha with special reference to Type II Diabetes Mellitus

Khobarkar Punam Self0 sites80 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
Khobarkar Punam Self
Enrollment
80
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
May 31, 2020
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Khobarkar Punam Self

Eligibility Criteria

Inclusion Criteria

  • 1\. Newly detected patients having fasting blood sugar level more than 126mg/dl and post prandial blood sugar level more than 200mg/dl (A.D.A 2015\)
  • 2\. Newly detected patients fulfilling criteria of diagnosis and having signs and symptoms of Sthula Madhumeha (Diabetes Mellitus)
  • 3\. Patients having age between 30 to 70 years
  • 4\. HbA1c up to 9%
  • 5\. Patients having BMI more than 23 will be selected up to 30 (chamukuttan.s.2006\)
  • 6\. Those are willing to participate in trial and ready to give written consent.
  • 7\. Patients with controlled Hypertension

Exclusion Criteria

  • 1\. Patients having age below 30 and above 70\.
  • 2\. Patients with fasting blood sugar level \>200mg/dl and post meal blood sugar level \>300mg/dl.
  • 3\. HbA1c more than 9%.
  • 4\. Patients having BMI less than 23 and above 30\.
  • 5\. Patients who already taken anti Diabetic drugs
  • 6\. Patients having insulin dependent diabetes mellitus and juvenile diabetes
  • 7\. Patients having complications such as vasculopathy, nephropathy, retinopathy and neuropathy.
  • 8\. Those are not willing to participate in trial and not ready to give written consent.
  • 9\. Patients having other systemic complications like hepatic, renal and cardiac problems.
  • 10\. If any complication arises during treatment or if any patient discontinues the treatment these cases will be liable for rejection.

Outcomes

Primary Outcomes

Not specified

Similar Trials